pentobarbital will lower the level or outcome of donepezil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unknown.
pentobarbital will decrease the level or impact of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unidentified.
pentobarbital will lower the level or outcome of etravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Warning is warranted for individuals with renal and hepatic impairment. When the manufacturer won't offer certain dosage adjustment tips for renal impairment, monitoring kidney function when administering substantial doses or conducting extended therapy is critical.
pentobarbital will decrease the extent or effect of alosetron by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.
Stay clear of; coadministration with CYP3A inducers might bring about decreased plasma concentrations of elvitegravir and/or maybe a concomitantly administered protease inhibitor and lead to lack of therapeutic impact also to achievable resistance
pentobarbital will reduce the extent or outcome of cevimeline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
pentobarbital will lessen the level or influence of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead on into a minimize in fentanyl plasma concentrations, insufficient efficacy or, maybe, improvement of the withdrawal syndrome in a affected person who's got developed Bodily dependence to fentanyl.
pentobarbital will decrease the level or outcome of buprenorphine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital decreases levels of elvitegravir/cobicistat/emtricitabine/tenofovir DF by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May possibly result in lack of virologic response and possible resistance.
benzhydrocodone/acetaminophen and pentobarbital equally boost sedation. Steer clear of or Use Alternate Drug. Limit use to clients for whom different remedy alternatives are inadequate
pentobarbital will reduce the level or influence of budesonide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Observe Closely (1)pentobarbital will lower the extent or impact of fentanyl transmucosal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of fentanyl with CYP3A4 inducers could lead on to a lessen in fentanyl plasma concentrations, lack of efficacy or, potentially, development of a withdrawal website syndrome inside of a affected person who's got developed Bodily dependence to fentanyl. After halting a CYP3A4 inducer, as the effects on the inducer drop, the fentanyl plasma concentration will enhance which could maximize or prolong equally the therapeutic and adverse consequences.
Contraindicated (1)pentobarbital will reduce the level or outcome of fostemsavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism.